Publication | Open Access
Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes: The FIDELIO-DKD Subgroup from China
19
Citations
21
References
2023
Year
Finerenone resulted in lower risks of CKD progression than placebo and a balanced safety profile in Chinese patients with CKD and T2DM.
| Year | Citations | |
|---|---|---|
Page 1
Page 1